Pleocytosis after hemopoietic stem cell transplantation.
Frequency and clinical significance of cerebrospinal fluid (CSF) pleocytosis in hemopoietic stem cell (HSC) transplantation were surveyed. Cyclosporine (CSA)- or tacrolimus (FK506)-based regimens were used as graft-vs-host disease (GVHD) prophylaxis in allogeneic HSC transplantation. CSF pleocytosis with or without neurologic symptoms was detected in 12 of 25 patients receiving allogeneic HSC transplants but in none of 11 patients receiving autologous HSC transplants. Of the 12 patients with CSF pleocytosis, only one patient developed leukoencephalopathy later. There was a correlation between CSF cell numbers and trough levels of CSA but not with those of FK506. In patients receiving allogeneic HSC transplants, CSF pleocytosis may be relatively common and may reflect neurologic damage associated with calcineurin inhibitors.
Nagashima
Takahiro
T
Division of Cell Therapy, Jichi Medical School Hospital, Minamikawachi-machi, Kawachi-gun, Tochigi-ken, Japan.
Muroi
Kazuo
K
Kawano-Yamamoto
Chizuru
C
Miyoshi
Takuji
T
Tatara
Raine
R
Meguro
Akiko
A
Fujiwara
Shin-Ichiro
S
Obara
Yoko
Y
Oh
Iekuni
I
Kikuchi
Satoru
S
Sato
Kazuya
K
Matsuyama
Tomohiro
T
Toshima
Masaki
M
Ohmine
Ken
K
Ozaki
Katsutoshi
K
Takatoku
Masaaki
M
Mori
Masaki
M
Nagai
Tadashi
T
Ozawa
Keiya
K
D000328:Adult; D002452:Cell Count; D002555:Cerebrospinal Fluid / Q000166:cytology*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007964:Leukocytosis / Q000139:chemically induced / Q000209:etiology*; D008297:Male; D011292:Premedication / Q000379:methods; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D016572:Cyclosporine; D016559:Tacrolimus